Dr. Schuchter's article explores the theoretical and practical aspects underlying the concept of cytoprotection, which has been recently introduced into the therapeutic armamentarium. Cytoprotection is contrasted with the related strategy of rescue, which has been widely applied since the cytokines granulocyte colony-stimulating factor (G-CSF, filgrastim [Neupogen]) and granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim [Leukine, Prokine]) obtained FDA approval.
A total of 332 patients with advanced non-small-cell lung cancer were randomized by the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative
The administration of intensive chemotherapy according to a rigid schedule improves response rates and duration of response. However, dose-limiting toxicities and resulting delays in therapy often interfere with therapy
When administered as a single agent in pretreated patients with advanced breast cancer, paclitaxel (Taxol) exhibits remarkable antitumor activity. This trial was undertaken to compare paclitaxel with standard
Paclitaxel (Taxol) has aroused considerable interest for its high single-agent activity in breast cancer and novel mechanism of action. Epirubicin (Farmorubicin), the 4'epimer of doxorubicin (Adriamycin), also has high activity in
PHILADELPHIA--The Board of Directors of the National Comprehensive Cancer Network (NCCN) has elected Robert C. Young, MD, to the position of Chairman of the Board. Dr. Young, currently president of the Fox Chase Cancer Center, is internationally known for his work in the treatment of lymphoma and ovarian cancer.
PARIS--A new formulation of doxorubicin in "stealth" liposomes (Doxil) provides durable responses in refractory epithelial ovarian cancer and primary peritoneal cancer, while apparently sidestepping the cardiotoxicity that limits the continued use of free doxorubicin in responding patients, according to two phase II studies performed at the University of Southern California (USC), Los Angeles.
Optimal dosing and scheduling are among the most important issues being addressed in clinical studies of the taxanes. The results to date indicate that there may not be a single administration schedule that produces optimal antitumor efficacy. Instead, the specific doses of the taxanes relative to each schedule and the overall aggressiveness of the dosing schedule should be considered. There appears to be a threshold taxane dose or concentration below which only negligible antitumor activity is observed, as well as a plateau dose or concentration above which no further antitumor activity occurs. The doses at which both threshold effects and plateauing of dose-response curves occur seem to be inversely proportional to the duration of the administration schedule. For paclitaxel (Taxol), it appears that comparable antitumor effects are achieved with both short (1- and 3-hour) and prolonged (24- and 96-hour) schedules as long as equitoxic dosing regimens are used. The majority of clinical studies with docetaxel have used a somewhat aggressive dosing schedule, 100 mg/m² over 1 hour, which marks the outer edge of the dosing envelope, but nonrandomized trial results suggest a dose-response relationship in the 60- to 100-mg/m² dosing range. [ONCOLOGY 11(Suppl):7-19, 1997]
The proven safety profile and antitumor activity of paclitaxel (Taxol) in the treatment of metastatic breast cancer led investigators at Memorial Sloan-Kettering Cancer Center (MSKCC) to further examine the agent's potential in the treatment of advanced breast cancer. Efficacy and tolerability studies of paclitaxel as single-agent therapy were undertaken, along with parallel investigations of quality-of-life parameters. The studies examined the effects of 96-hour infusion schedules of paclitaxel and are currently assessing the feasibility of a weekly 1-hour infusion schedule. Researchers at MSKCC also compared the results of a variety of two- and three-drug paclitaxel-containing regimens to determine possible synergism and better define safety profiles. They examined the combination of paclitaxel and edatrexate, as well as a promising combination of paclitaxel and a monoclonal antibody directed at growth factor receptors. The latter ongoing trial will include both laboratory studies that examine possible cellular mechanisms for the combination's observed synergy and a clinical trial that combines paclitaxel with a monoclonal antibody directed against the epidermal growth factor. In conclusion, the investigators discuss the optimal integration of paclitaxel into doxorubicin/cyclophosphamide (Cytoxan, Neosar)-based adjuvant therapy for node-positive stage II-III resectable breast cancer. [ONCOLOGY 11(Suppl):20-28, 1997]
By engineering proteins that coagulate the blood that feeds malignant tumors, scientists at UT Southwestern Center at Dallas have succeeded in destroying malignancies in mice. This therapy is expected to be effective against all major cancers, with
BETHESDA, Md--Hoping to resolve one of cancer care's ongoing controversies, the National Cancer Institute is launching the first large national study of high-dose chemotherapy for advanced ovarian cancer, to be conducted at dozens of medical centers affiliated with the Gynecologic Oncology Group and other cooperative groups supported by NCI.
In an effort to resolve one of the ongoing controversies in cancer care, the National Cancer Institute (NCI) has launched the first large national study of high-dose chemotherapy for ovarian cancer with transplantation of bone marrow blood stem cells.
ATLANTA-A study of more than 400,000 postmenopausal women has found no increased risk of fatal breast cancer with use of estrogen replacement therapy (ERT). In fact, women who reported ever having used estrogen actually had a 16% decreased risk of dying of breast cancer, Dawn Willis, PhD, MPH, reported for the American Cancer Society (ACS) at a general session of the San Antonio Breast Cancer Symposium.
NASHVILLE-In 1996, delivery difficulties were the major barrier to breast cancer gene therapy, Jeffrey T. Holt, MD, said at a plenary session of the San Antonio Breast Cancer Symposium.
VIENNA--For women with advanced epithelial ovarian cancer who fail one platinum-based regimen, topotecan (Hycamtin) may represent a promising alternative to paclitaxel (Taxol), reported W. W. ten Bokkel Huinink, MD, of the Netherlands Cancer Institute.
COLUMBUS, Ohio--Many of the diagnostic tests and procedures following treatment for breast cancer fail to extend survival, as demonstrated by two randomized, prospective studies and nine retrospective studies, said Victor G. Vogel, MD, MHS, director of the Comprehensive Breast Cancer Program at the University of Pittsburgh.
VIENNA--The identification of genes that predispose to cancer raises two dilemmas for clinical oncologists. The first is whether to offer genetic testing to healthy relatives of cancer patients who carry a culprit gene, and the second, thornier problem is whether advice for healthy carriers should extend beyond avoidance of risk factors and regular screening.
Distinct cellular anomalies have been found with far greater frequency in the ovaries of women at high risk of ovarian cancer than in the ovaries of women whose organs were removed for non-cancer-related reasons. This finding may provide clues to
NEW YORK--Three types of genetic modification--chemosensitization of cancer cells, suppression of oncogene function, and chemoprotection of hematopoietic cells--are under study as a means of improving cancer treatment, Albert Deisseroth, MD, PhD, said at the 15th International Bayer Pharma Press Seminar.
Moving into the final recruitment phase, the researchers of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) are seeking 75,000 more men and women ages 55 to 74 to help them determine whether medical tests to detect some of the most common cancers reduce the number of deaths from these diseases. This largest-ever US cancer screening trial will include a total of 148,000 men and women in 10 cities: Denver, Colorado; Washington, DC; Honolulu, Hawaii; Detroit, Michigan; Minneapolis, Minnesota; St Louis, Missouri; Brooklyn, New York; Pittsburgh, Pennsylvania; Salt Lake City, Utah; and Marshfield, Wisconsin.
WASHINGTON--An analysis from the National Cancer Institute, drawing on data from the Surveillance, Epidemiology, and End Results program (SEER) and from the National Center for Health Statistics, has found a 5-year decline of 2.6% in overall cancer mortality (see chart on page 1).
According to a new study published in the October 1, 1996, issue of Blood, Hycamtin (topotecan hydrochloride) offers a promising new treatment option for patients suffering from myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML). Patients treated with topotecan achieved a complete response rate of 28%, while currently used single-agent therapies have traditionally achieved a complete response rate of only 10% to 15% among this high-risk patient group. Topotecan, a topoisomerase I inhibitor marketed by SmithKline Beecham, is currently indicated for the treatment of patients with recurrent, metastatic ovarian cancer.
Oncologists still have no screening test that reliably can detect ovarian cancer in its early stages, and recent genetic advances, while shedding new light on the disease, have further complicated the issue.
SALT LAKE CITY--Myriad Genetic Laboratories, Inc. and the American College of Surgeons (ACS) have announced a long-term study that will follow the outcomes of patients currently undergoing BRCA1 genetic analysis for breast and ovarian cancer susceptibility.
Strategies for chemopreventative drug development are based on the use of well-characterized agents, intermediate biomarkers correlating to cancer incidence, and suitable cohorts for efficacy studies. Since
